Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study
Issued Date
2024-01-01
Resource Type
eISSN
26665247
Scopus ID
2-s2.0-85188992537
Journal Title
The Lancet Microbe
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet Microbe (2024)
Suggested Citation
Pakdeerat S., Boonklang P., Angchagun K., Chomkatekaew C., Apichaidejudom N., Dokket Y., Faosap A., Wongsuwan G., Wuthiekanun V., Aramrueung P., Khamnoi P., Thananchai H., Siriboon S., Chamnan P., Peacock S.J., Day N.P.J., Thomson N.R., Uttamapinant C., Wongpalee S.P., Chewapreecha C. Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study. The Lancet Microbe (2024). doi:10.1016/S2666-5247(23)00378-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97889
Title
Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study
Author's Affiliation
Faculty of Tropical Medicine, Mahidol University
Mahidol Oxford Tropical Medicine Research Unit
Department of Medicine
Vidyasirimedhi Institute of Science and Technology
Faculty of Medicine, Chiang Mai University
Maharaj Nakorn Chiang Mai Hospital
Nuffield Department of Medicine
Wellcome Sanger Institute
Sunpasitthiprasong Hospital
Mahidol Oxford Tropical Medicine Research Unit
Department of Medicine
Vidyasirimedhi Institute of Science and Technology
Faculty of Medicine, Chiang Mai University
Maharaj Nakorn Chiang Mai Hospital
Nuffield Department of Medicine
Wellcome Sanger Institute
Sunpasitthiprasong Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Melioidosis is a neglected but often fatal tropical disease. The disease has broad clinical manifestations, which makes diagnosis challenging and time consuming. To improve diagnosis, we aimed to evaluate the performance of the CRISPR-Cas12a system (CRISPR-BP34) to detect Burkholderia pseudomallei DNA across clinical specimens from patients suspected to have melioidosis. Methods: We conducted a prospective, observational cohort study of adult patients (aged ≥18 years) with melioidosis at Sunpasitthiprasong Hospital, a tertiary care hospital in Thailand. Participants were eligible for inclusion if they had culture-confirmed B pseudomallei infection from any clinical samples. Data were collected from patient clinical records and follow-up telephone calls. Routine clinical samples (blood, urine, respiratory secretion, pus, and other body fluids) were collected for culture. We documented time taken for diagnosis, and mortality at day 28 of follow-up. We also performed CRISPR-BP34 detection on clinical specimens collected from 330 patients with suspected melioidosis and compared its performance with the current gold-standard culture-based method. Discordant results were validated by three independent qualitative PCR tests. This study is registered with the Thai Clinical Trial Registry, TCTR20190322003. Findings: Between Oct 1, 2019, and Dec 31, 2022, 876 patients with culture-confirmed melioidosis were admitted or referred to Sunpasitthiprasong Hospital, 433 of whom were alive at diagnosis and were enrolled in this study. Median time from sample collection to diagnosis by culture was 4·0 days (IQR 3·0–5·0) among all patients with known survival status at day 28, which resulted in delayed treatment. 199 (23%) of 876 patients died before diagnosis and 114 (26%) of 433 patients in follow-up were treated, but died within 28 days of admission. To test the CRISPR-BP34 assay, we enrolled and collected clinical samples from 114 patients with melioidosis and 216 patients without melioidosis between May 26 and Dec 31, 2022. Application of CRISPR-BP34 reduced the median sample-to-diagnosis time to 1·1 days (IQR 0·7–1·5) for blood samples, 2·3 h (IQR 2·3–2·4) for urine, and 3·3 h (3·1–3·4) for respiratory secretion, pus, and other body fluids. The overall sensitivity of CRISPR-BP34 was 93·0% (106 of 114 samples [95% CI 86·6–96·9]) compared with 66·7% (76 of 114 samples [57·2–75·2]) for culture. The overall specificity of CRISPR-BP34 was 96·8% (209 of 216 samples [95% CI 93·4–98·7]), compared with 100% (216 of 216 samples [98·3–100·0]) for culture. Interpretation: The sensitivity, specificity, speed, and window of clinical intervention offered by CRISPR-BP34 support its prospective use as a point-of-care diagnostic tool for melioidosis. Future development should be focused on scalability and cost reduction. Funding: Chiang Mai University Thailand and Wellcome Trust UK.